Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.65 USD | -2.37% | -6.30% | -16.29% |
22/04 | Citigroup Starts Coverage on Evolent Health With Buy Rating, $40 Price Target | MT |
28/03 | Canaccord Genuity Trims Price Target on Evolent Health to $44 From $45, Maintains Buy Rating | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 68% by 2026.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- Low profitability weakens the company.
- With an expected P/E ratio at 1199.05 and 57.43 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-16.29% | 3.17B | C- | ||
+4.36% | 32.47B | C | ||
+15.21% | 7.45B | C- | ||
+22.93% | 3.89B | B- | ||
-25.96% | 1.28B | B | ||
-36.14% | 1.09B | - | ||
-35.42% | 902M | - | ||
-0.13% | 893M | C | ||
-24.12% | 857M | - | C+ | |
-18.47% | 693M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- EVH Stock
- Ratings Evolent Health, Inc.